Clinical Trials on Hemophilia A or B

Total 2590 results

Weill Medical College of Cornell University
Bayer; University Hospital, Bonn

Completed

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

Hemophilia A | Hemophilia B

United States, Israel, Australia, Italy, Sweden, Germany, Japan, Netherlands, Taiwan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX

Hemophilia B

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use

Hemophilia B

Belgium, Spain, Italy, Austria, United Kingdom, Netherlands, Sweden, Germany, Portugal, France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating rFIX; BeneFIX® in Hemophilia B

Hemophilia B

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Approach to Treatment of Haemophilia A and B in Spain

Hemophilia A | Hemophilia B
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

Hemophilia B
Prothya Biosolutions

Completed

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Hemophilia B

Netherlands
Universitaire Ziekenhuizen KU Leuven
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait. (3DMKFM)

Arthropathy | Haemophilia
Volkan Deniz, PT

Completed

The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients.

Haemophilia

Turkey
University of Valencia
Shire

Completed

A Progressive Resistance Training Program in Patients With Haemophilia

Haemophilia

Spain
ANA TORRES-ORTUÑO
Pfizer

Unknown

Adherence to Treatment in Hemophilia (ADHERENCE)

Haemophilia

Spain
Investigación en Hemofilia y Fisioterapia

Not yet recruiting

Clinical, Functional and Musculoskeletal Differences Between Adult Patients With Hemophilia and Their Healthy Peers

Hemophilia Arthropathy
Real Fundación Victoria Eugenia
Universidad de Murcia; Medtep Inc.

Unknown

Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia (uPatient)

Haemophilia
Real Fundación Victoria Eugenia
Medtep Inc.

Unknown

Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia

Haemophilia

Spain
St. Jude Children's Research Hospital

Recruiting

Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy

Hemophilia B | Gene Therapy

United States
Baxalta now part of Shire

Active, not recruiting

Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

Hemophilia B

United States
Ultragenyx Pharmaceutical Inc

Completed

Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Hemophilia B

United States, United Kingdom
Baxalta now part of Shire

Completed

Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia

Hemophilia A | Hemophilia B

United States, Spain, Italy, Germany, France, Austria
Spark Therapeutics
Children's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaborators

Terminated

Hemophilia B Gene Therapy With AAV8 Vector

Hemophilia B

United States, Australia
Ultragenyx Pharmaceutical Inc

Terminated

Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

Hemophilia B

United States, United Kingdom, Bulgaria
Equilibra Bioscience LLC

Recruiting

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)

Hemophilia A | Hemophilia B | Healthy Participants

United States
Shanghai Belief-Delivery BioMed Co., Ltd

Active, not recruiting

Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

Hemophilia B

China
Baxalta now part of Shire

Terminated

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Hemophilia B

Turkey, Spain
University of Miami
Shire

Terminated

The Hemophilia Ultrasound Project (HUP)

Hemophilia A | Hemophilia B

United States
Cliniques universitaires Saint-Luc- Université...

Completed

Gait Evaluation in Haemophiliac Patients (GAIT_GENERAL)

Hemophilia A | Hemophilia B

Belgium
Avigen
The University of Texas Health Science Center, Houston; Children's Hospital... and other collaborators

Terminated

Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B

Hemophilia B

United States
Pfizer

Completed

Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe

Factor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
Universidad de Murcia

Unknown

Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia. (ADHAESIONE)

Haemophilia

Spain
CSL Behring

Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B

United States, Canada, Israel
Institute of Hematology & Blood Diseases Hospital
East China University of Science and Technology

Active, not recruiting

Gene Therapy for Chinese Hemophilia B

Hemophilia B

China
Baxalta now part of Shire

Completed

IMMUNINE Pre-Treatment Study

Hemophilia B

Colombia, Bulgaria, Chile, Poland, Romania, Argentina, Brazil, Czechia, Russian Federation, Ukraine
Spark Therapeutics
Children's Hospital of Philadelphia; Royal Prince Alfred Hospital, Sydney,... and other collaborators

Completed

LTFU for Gene Transfer Subjects With Hemophilia B

Hemophilia B

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (pathfinder8)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Switzerland, Taiwan, Turkey, United Kingdom, Croatia, Germany, Brazil, France, Japan, Australia, Hungary, Israel, Korea, Republic of, Lithuania, Portugal, Ukraine, Greece, Italy, Denmark, Norway, Canada and more
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
Novo Nordisk A/S

Completed

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Austria, Spain, Poland, United Kingdom, Croatia, Germany, Malaysia, Australia, France, Israel, Thailand, Ukraine, Turkey
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)

Congenital Bleeding Disorder | Haemophilia A

United States, Macedonia, The Former Yugoslav Republic of, Serbia, Malaysia, Brazil, Turkey, Lithuania, Russian Federation, Italy, Japan, Poland, Puerto Rico, Taiwan
Novo Nordisk A/S

Completed

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Congenital Bleeding Disorder | Haemophilia A

Japan
Tri-Service General Hospital

Completed

Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy

Hemophilia | Hemophilic Arthropathy
Universidad Católica San Antonio de Murcia

Completed

Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy (PROPRIO-HE)

Hemophilia

Spain
Novo Nordisk A/S

Completed

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Congenital Bleeding Disorder | Haemophilia A

Mexico
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany
Novo Nordisk A/S

Completed

Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (guardian ™9)

Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United States, Germany, Serbia, Taiwan, Bulgaria
Novo Nordisk A/S

Completed

A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (pathfinder™7)

Congenital Bleeding Disorder | Haemophilia A

United States, Netherlands, Spain, Germany, France, Denmark
The Hospital for Sick Children
Baxter Healthcare Corporation; University of Sao Paulo; University of Campinas... and other collaborators

Completed

Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles

Hemophilia | Hemophilic Arthropathy

Canada, Brazil
Universidad de Murcia

Completed

Multidisciplinary Evaluation of Patients With Hemophilia (HOLISTIC)

Haemophilia

Spain
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PUPs B-LONG)

Hemophilia B

United States, Italy, Ireland, New Zealand, United Kingdom, Australia, Netherlands, Denmark, Poland, Sweden, France
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine

Clinical Trials on Hemophilia A or B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations